1. Home
  2. SIDU vs MGNX Comparison

SIDU vs MGNX Comparison

Compare SIDU & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sidus Space Inc.

SIDU

Sidus Space Inc.

HOLD

Current Price

$2.00

Market Cap

243.4M

ML Signal

HOLD

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

HOLD

Current Price

$4.30

Market Cap

220.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SIDU
MGNX
Founded
2012
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
243.4M
220.6M
IPO Year
2021
2013

Fundamental Metrics

Financial Performance
Metric
SIDU
MGNX
Price
$2.00
$4.30
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$5.00
AVG Volume (30 Days)
9.1M
1.4M
Earning Date
05-14-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
66.94
N/A
EPS
N/A
N/A
Revenue
$3,383,878.00
$149,500,000.00
Revenue This Year
$171.29
N/A
Revenue Next Year
N/A
$3.19
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.63
$1.30
52 Week High
$6.79
$5.08

Technical Indicators

Market Signals
Indicator
SIDU
MGNX
Relative Strength Index (RSI) 31.38 48.41
Support Level $1.90 $1.49
Resistance Level $3.12 $4.55
Average True Range (ATR) 0.23 0.33
MACD -0.03 -0.07
Stochastic Oscillator 4.87 20.22

Price Performance

Historical Comparison
SIDU
MGNX

About SIDU Sidus Space Inc.

Sidus Space Inc is a space and defense technology company with core capabilities that include dual use satellite manufacturing & technology integration, AI products and services, space and defense hardware components and space-based data solutions. The company generates revenue through a combination of: Satellite platform sales and customization, Payload hosting and mission services, Engineering and systems integration services, and Space and defense hardware manufacturing. The firm supports Commercial Space, Aerospace, Defense, Underwater Marine, and other commercial and government customers. The firm generates revenue principally from satellite platform and payload hosting contracts, manufacturing and engineering services, mission operations, and sales of proprietary hardware products.

About MGNX MacroGenics Inc.

Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.

Share on Social Networks: